anti icos mab  (Bio X Cell)

Journal: Journal of translational medicine

Article Title: Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model.

doi: 10.1186/s12967-024-05899-w

Figure Lengend Snippet: Fig. 4 A Scheme of Cy7 NHS ester conjugation with anti-human ICOS monoclonal antibody (mAb). B The characterization of labeled antibody at differ ent concentrations. Relative fluorescence unit (RFU). C Cell uptake of Cy7-ICOS mAb in PMA/Iono activated, blocked, and resting T cells in huPBMCs at 1-hour incubation (n = 3). D MFI was measured to assess cellular uptake of the ICOS mAb labeled with Cy7 fluorophore at a concentration of 100nM. All values represent the mean ± SEM unless otherwise specified. One-way ANOVA and t test was conducted for statistical significance. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns p > 0.05

Article Snippet: The supplier of the in vivo monoclonal antibody (BE0353, clone: C398.4 A) against human ICOS was BioXCell, located in West Lebanon, USA.

Techniques: Conjugation Assay, Labeling, Fluorescence, Incubation, Concentration Assay

Journal: Journal of translational medicine

Article Title: Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model.

doi: 10.1186/s12967-024-05899-w

Figure Lengend Snippet: Fig. 5 A Reference of 4-view Regions of Interest (ROI) drawing was implemented, encompassing perspectives from the TOP, Bottom, Left, and Right orientations. B 4-view NIRF images at all time points (24 h, 48 h, 72 h, 96 h) between the huPBMC-AIA (n = 6) and control groups (n = 4). C X-ray and photographs images merge NIRF imaging following ICOS mAb-Cy7 injection at 6 h, 24 h, 48 h, 72 h and 96 h. D Fluorescence Intensity (FI) of four distinct views was systematically assessed at various time points. E ROI quantification of RP and the RP/LP ratio at all time points examined between huPBMC-AIA and control. F Correlation between paw thickness and RP/LP ratio in NIRF. Significant correlation was observed in both huPBMC-AIA and control group. All values represent the mean ± SEM unless otherwise specified. One-way ANOVA and t test was conducted for statistical significance. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns p > 0.05

Article Snippet: The supplier of the in vivo monoclonal antibody (BE0353, clone: C398.4 A) against human ICOS was BioXCell, located in West Lebanon, USA.

Techniques: Control, Imaging, Injection, Fluorescence

Journal: Journal of translational medicine

Article Title: Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model.

doi: 10.1186/s12967-024-05899-w

Figure Lengend Snippet: Fig. 6 A Ex vivo imaging in major organs (1 heart, 2 liver, 3 lung, 4 spleen, 5 kidney, 6 intestine, 7 right paw (RP), 8 left paw (LP), 9 bone, 10 muscle, 11 skin, and 12 blood) at day 7 right after the last in vivo NIRF scan (X-ray and photographs images). B Fluorescence intensity (FI) statistics were analyzed for both paw tissues and major organs following the intravenous administration of ICOS mAb labeled with Cy7 fluorophore at the 96 h time point. C Intra-group correlation analysis, the uptake and metabolism of the anti-human ICOS-Cy7 were evaluated. Row/column order determined by unsupervised hierarchi cal clustering. Side bars represent log10 (FI of organs) at 96 h. D Correlogram depicting r2 Pearson correlation between FI measured in the indicated ROI, compared with the log10 (fold-change RP/LP)at various time points. E Principal Component Analysis (PCA) involved the transformation of the data into principal components, enabling a comprehensive exploration of patterns and variations within the normalized ICOS NIRF signals. F ROC analysis showing sensitivity against 100%specificity for distinguishing the huPBMC-AIA from control group based on FI fold change imaged at 24 h and 96 h. All values represent the mean ± SEM unless otherwise specified. One-way ANOVA and t test was conducted for statistical significance. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns p > 0.05

Article Snippet: The supplier of the in vivo monoclonal antibody (BE0353, clone: C398.4 A) against human ICOS was BioXCell, located in West Lebanon, USA.

Techniques: Ex Vivo, Imaging, In Vivo, Fluorescence, Labeling, Transformation Assay, Control

Journal: Cell Reports Medicine

Article Title: Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures

doi: 10.1016/j.xcrm.2025.101934

Figure Lengend Snippet:

Article Snippet: Anti-ICOS (D1K2T) Rabbit Monoclonal Primary Antibody , CST , 89601.

Techniques: Software, Clinical Proteomics, Imaging

Journal: Cancer Immunology Research

Article Title: Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment

doi: 10.1158/2326-6066.CIR-23-1092

Figure Lengend Snippet: FH binds to T cells via ICOS. A, Biotinylated FH binds to CD4 + T cells upon incubation for 2 hours with TexMACS medium alone and supplemented with 50 and 100 μg/mL FH. B, Fractionation detecting FH binding but not internalization into CD4 + T cells, incubated with 150 μg/mL FH for 2 hours at 4°C or 37°C. C, HuProt microarray showing top-specific proteins binding FH CCP19-20. D and E, PLA showing FH binding to ICOS. CD4 + T cells and activated CD4 + T cells were incubated with FH for 2 hours at 37°C, and the interaction between ICOS and FH was detected with specific antibodies and visualized as white dots. F, ELISA detection of dose-dependent binding of FH to ICOS or α1-AT. CD4 + T cells were incubated for 2 hours at 37°C with biotinylated FH or α1-AT and lysed. The microtiter plate was coated with an anti-ICOS antibody, and bound complexes from the lysates were detected with streptavidin. G, Preincubation with anti-ICOS antibody reduced FH binding to CD4 + T cells in a dose-dependent manner. Isotype control was used at the same concentration, without affecting the binding. Representative blot ( H ) and quantification ( I and J ) of increased phosphorylation of Akt and GSK in Tregs upon incubation with 150 μg/mL FH. ICOS blocking antibody but not isotype control inhibited this effect. Data are means ± SD of n = 8 ( A ), n = 5 ( E–G Iso-CTRL), n = 7 ( G α-ICOS), n = 4 ( I and J ) independent experiments; representative blot of ( B and H ) n = 4 independent experiments; representative pictures of ( D ) n = 5 independent experiments. Statistical test: Kruskal–Wallis with Dunn’s multiple comparison test ( A and E ), two-way ANOVA ( F and G ), and one-way ANOVA ( I and J ) with Tukey’s multiple comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. act, activated; AF, Alexa Fluor; CTRL, control; GSK, glycogen synthase kinase-3; iso, isotype; ns, nonsignificant; PLA, proximity ligation assay.

Article Snippet: Blocking and permeabilization were performed with 0.5% Triton X-100 in PBS with 1% BSA for 20 minutes, followed by incubation in blocking solution overnight at 4°C with the following primary antibodies: FH (Santa Cruz Biotechnology, Cat. # sc-17951, RRID:AB_2260590), GFAP (Abcam, Cat. # ab4674, RRID:AB_304558), Olig2 (R and D Systems, Cat. # AF2418, RRID:AB_2157554), F4/80 (BioLegend, Cat. # 123117, RRID:AB_893489), CD4 (Abcam, Cat. # ab183685, RRID:AB_2686917), CD8-Alexa 555 (Abcam, Cat. # ab280863, RRID:AB_2927548), FoxP3 (Thermo Fisher Scientific, Cat. # 14-5773-82, RRID:AB_467576), Ki67 (Abcam, Cat. # ab156956, RRID:AB_2732028), ICOS (Cell Signaling Technology, Cat. # 67223, RRID:AB_3096171), and goat IgG (R and D Systems, Cat. # AB-108-C, RRID:AB_354267).

Techniques: Incubation, Fractionation, Binding Assay, Microarray, Enzyme-linked Immunosorbent Assay, Control, Concentration Assay, Phospho-proteomics, Blocking Assay, Comparison, Proximity Ligation Assay